abrdn plc Acquires Shares of 1,452,741 Oculis Holding AG (NASDAQ:OCS)

abrdn plc purchased a new stake in Oculis Holding AG (NASDAQ:OCS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,452,741 shares of the company’s stock, valued at approximately $15,980,000. abrdn plc owned approximately 3.99% of Oculis as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of OCS. Compagnie Lombard Odier SCmA boosted its holdings in Oculis by 47.3% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in Oculis in the 3rd quarter worth about $77,000. Finally, Barclays PLC acquired a new position in shares of Oculis during the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Performance

NASDAQ OCS opened at $11.98 on Thursday. Oculis Holding AG has a 1 year low of $9.05 and a 1 year high of $14.50. The company has a fifty day moving average of $11.89 and a two-hundred day moving average of $11.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, equities analysts anticipate that Oculis Holding AG will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on OCS shares. Chardan Capital restated a “buy” rating and set a $30.00 target price on shares of Oculis in a report on Tuesday, March 19th. HC Wainwright decreased their price objective on Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday. Robert W. Baird decreased their price objective on Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, March 19th. Finally, Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Oculis in a report on Wednesday, March 6th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis currently has an average rating of “Buy” and an average target price of $29.14.

Oculis Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.